CD19-targeting fusion protein combined with PD1 antibody enhances anti-tumor immunity in mouse models.
B cell vaccine
CD19
anti-PD1
breast cancer
combination therapy
immunotherapy
Journal
Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2020
2020
Historique:
received:
01
11
2019
revised:
04
03
2020
accepted:
17
03
2020
entrez:
5
5
2020
pubmed:
5
5
2020
medline:
5
5
2020
Statut:
epublish
Résumé
In our previous studies, using a B cell vaccine (scFv-Her2), the targeting of tumor-associated antigen Her2 (human epidermal growth factor receptor-2) to B cells via the anti-CD19 single chain variable fragment (scFv) was shown to augment tumor-specific immunity, which enhanced tumor control in the prophylactic and therapeutic setting. However, the fusion protein displayed limited activity against established tumors, and local relapses often occurred following scFv-Her2 treatment, indicating that scFv-Her2-induced responses are inadequate to maintain anti-tumor immunity. In this study, targeting the IV region (D4) of the extracellular region of Her2 to B cells via CD19 molecules (scFv-Her2
Identifiants
pubmed: 32363119
doi: 10.1080/2162402X.2020.1747688
pii: 1747688
pmc: PMC7185221
doi:
Substances chimiques
Antigens, CD19
0
CD19 antigen, mouse
0
Cancer Vaccines
0
Recombinant Fusion Proteins
0
Erbb2 protein, mouse
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
1747688Informations de copyright
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.
Références
Cancer Cell. 2015 Apr 13;27(4):450-61
pubmed: 25858804
Sci Transl Med. 2014 Feb 19;6(224):224ra25
pubmed: 24553386
Oncotarget. 2015 Mar 10;6(7):5449-64
pubmed: 25669979
Trends Cancer. 2017 Sep;3(9):615-620
pubmed: 28867165
J Immunol. 2019 Oct 1;203(7):1715-1729
pubmed: 31484732
Oncoimmunology. 2019 Sep 20;8(12):e1659096
pubmed: 31741757
Ann Oncol. 2007 Jun;18(6):977-84
pubmed: 17229773
PLoS One. 2013 Oct 21;8(10):e77780
pubmed: 24204962
Eur J Immunol. 2016 Dec;46(12):2719-2729
pubmed: 27701733
Front Oncol. 2016 Nov 01;6:233
pubmed: 27847783
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Immunol Cell Biol. 2006 Jun;84(3):281-9
pubmed: 16681825
Gynecol Oncol. 2018 Nov;151(2):381-389
pubmed: 30217369
Nat Rev Immunol. 2014 Oct;14(10):705-11
pubmed: 25190285
Clin Colorectal Cancer. 2017 Dec;16(4):247-251
pubmed: 28363756
Cancer Immunol Immunother. 2019 Oct;68(10):1689-1700
pubmed: 31375885
Breast. 2018 Jun;39:80-88
pubmed: 29631097
Nat Immunol. 2013 Oct;14(10):996-1006
pubmed: 24048121
Front Immunol. 2014 May 30;5:255
pubmed: 24910635
Nature. 2003 Feb 13;421(6924):756-60
pubmed: 12610629
Immunity. 2000 Jul;13(1):47-57
pubmed: 10933394
Int J Clin Pharmacol Ther. 2004 Nov;42(11):642-3
pubmed: 15598031
J Immunol. 2013 Jun 1;190(11):5588-99
pubmed: 23630363
Front Oncol. 2012 Jun 18;2:62
pubmed: 22720269
Curr Top Microbiol Immunol. 2011;350:17-37
pubmed: 21061197
J Cancer Sci Ther. 2018;10(8):190-197
pubmed: 30393513
Curr Treat Options Oncol. 2019 Mar 28;20(4):35
pubmed: 30923913
Semin Cancer Biol. 2018 Oct;52(Pt 2):39-52
pubmed: 28987965
Rambam Maimonides Med J. 2015 Jan 29;6(1):e0004
pubmed: 25717386
Cancer Med. 2013 Oct;2(5):662-73
pubmed: 24403232
Bull Cancer. 2007 Mar;94(3):259-66
pubmed: 17371768
Expert Opin Ther Targets. 2011 Oct;15(10):1211-25
pubmed: 21870995
Front Immunol. 2018 Jun 13;9:1344
pubmed: 29951069
J Virol. 2012 Mar;86(5):2488-500
pubmed: 22205734
Cancer Lett. 2006 Feb 8;232(2):123-38
pubmed: 16458110
Front Immunol. 2019 Jan 29;10:59
pubmed: 30761131
Clin Cancer Res. 2019 Apr 1;25(7):2033-2041
pubmed: 30442682
Cell Stress. 2019 Jul 03;3(9):295-309
pubmed: 31535086
Annu Rev Immunol. 2007;25:267-96
pubmed: 17134371
Nat Rev Drug Discov. 2015 Aug;14(8):561-84
pubmed: 26228759
Nat Med. 2016 Jan;22(1):26-36
pubmed: 26735408
Blood. 2008 Oct 1;112(7):2817-25
pubmed: 18669871
Immunity. 2014 Jul 17;41(1):49-61
pubmed: 25035953
Nat Immunol. 2007 Mar;8(3):239-45
pubmed: 17304234
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Trends Immunol. 2016 Dec;37(12):844-854
pubmed: 27793570
Blood. 2018 Jan 4;131(1):68-83
pubmed: 29118007
J Immunol. 1999 May 15;162(10):5695-703
pubmed: 10229801
Front Immunol. 2018 Dec 20;9:3059
pubmed: 30619378
Cancer Immunol Immunother. 2019 Oct;68(10):1671-1680
pubmed: 30905043
Nat Immunol. 2008 Jan;9(1):63-72
pubmed: 18059271